August 5, 2020 -- Elios Therapeutics' personalized cancer vaccine shows a long-term survival benefit for patients with stage III or IV melanoma, according to final data from its clinical trial.
Three years after completing the vaccine series, 93% of high-risk melanoma patients remained alive, while 77% of patients who were given placebos survived, according to final data from a prospective, randomized, double-blind, placebo-controlled phase IIb clinical trial.
Elios' personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made from a patient's tumor and blood. Every patient's tumor has a unique antigenic profile unlike any other, and dendritic cells found in the blood are the most potent antigen-presenting cells in the body.
Copyright © 2020 scienceboard.net